Back to Results

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients with Monocytic Differentiation and in Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML) Patients

Primary Objective

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the MTD or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Outpatient CTRC
Pathology - SOM
University of Colorado Hospital

Principal Investigator
Dan Pollyea,  MD, MS

Dan Pollyea, MD, MS

Study ID

Protocol Number: 20-1388

More information available at ClinicalTrials.gov: NCT04372433

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers